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HIV-infected children are at high risk of contracting 
tuberculosis (TB). An incidence of 24 cases per 100 
HIV-infected children per year was documented in Cape 
Town during a period of limited access to antiretroviral 
therapy (ART).1 
For HIV-infected adults, IPT is a cornerstone of TB 
management. IPT for HIV-infected adults refers to 
giving INH to those without active TB. IPT, together 
with intensified case finding and infection control, is 
collectively referred to as the ‘3 Is’ strategy of the World 
Health Organization (WHO).2 In a recent meta-analysis 
of 12 trials and 8 578 randomised HIV-infected subjects 
>13 years of age, TB preventive therapy (any anti-TB 
drug) versus placebo resulted in a lower incidence of 
active TB (relative risk (RR) 0.68, 95% confidence interval 
(CI) 0.54 - 0.85). This effect was more pronounced in 
individuals with a positive tuberculin skin test (TST) (RR 
0.38, 95% CI 0.25 - 0.57). For adults with a negative TST, 
there was no statistically significant difference between 
treatment groups as the upper CI was >1 (RR 0.89, 95% 
CI 0.64 - 1.24). Compared with INH monotherapy, short-
course multidrug regimens had more adverse effects. 
A reduction in mortality with INH monotherapy versus 
placebo was confined to those with a positive TST (RR 
0.74, 95% CI 0.55 - 1.00).3 
The meta-analysis did not address the role of ART, 
which also reduces the risk of acquiring TB disease, 
as no randomised controlled trials have been reported 
in patients on ART. Lawn and colleagues have argued 
that ART and IPT have complementary roles, IPT being 
important in TST-positive individuals with higher CD4 
counts and better immunity, and that ART (together with 
active case finding) is the most important component in 
immunosuppressed individuals.4
A meta-analysis from 2006 showed that IPT is not 
associated with production of INH resistance,5 although 
resistance is a concern if patients have active disease 
before commencing IPT. It is also recognised that IPT 
is unlikely to prevent TB if a patient is infected with 
Mycobacterium tuberculosis resistant to INH.6
For children there are fewer data. The benefit of IPT after 
documented TB exposure or infection (TST positive) is 
undisputed, with the efficacy derived from studies in 
HIV-uninfected children.7 Findings assessing the value 
of universal IPT before or in the absence of documented 
exposure to a source case (pre-exposure IPT) seem 
contradictory. Zar and colleagues showed benefit in 
a double-blind study comparing INH with placebo in 
children with limited access to ART in Cape Town.1 
Active TB was excluded at baseline and children already 
responding to TB treatment were randomised once TB 
treatment had been completed. Mortality was lower in 
the INH group (11 (8%) v. 21 (16%)) (hazard ratio (HR) 
0.46, 95% CI 0.22 - 0.95, p=0.015). The incidence of TB 
was also lower in the INH group (5 cases, 3.8%) than in 
the placebo group (13 cases, 9.9%) (HR 0.28, 95% CI 
0.10 - 0.78, p=0.005).1 
A large multicentre trial set in Soweto, Cape Town and 
Durban enrolled infants between 3 and 4 months of 
age, after excluding all children with known TB contact. 
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HIV-infected children have a high risk of acquiring tuberculosis. The World Health Organization (WHO) has 
released isoniazid preventive therapy (IPT) recommendations for adults and children living with HIV, based on 
efficacy studies, mainly in adults. Data from children appear conflicting. IPT guidelines for children were developed 
in response to WHO guidelines at a local meeting, followed by discussions. 
IPT should be given to all HIV-infected children after exposure to a source case if treatment for active disease is 
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It took place during expanding access to ART. There 
was no benefit from pre-exposure IPT compared with 
placebo, either in preventing TB or in reducing mortality 
in HIV-infected and HIV-exposed uninfected infants.8,9 
The apparent contradiction with the study by Zar et 
al.1 could be explained by differences in the patient 
populations, excellent surveillance for TB exposure, and 
rapid institution of open-label INH for any documented 
exposure to a source case. The benefit of ART in 
reducing TB disease is well documented in children.10,11 
New long-term data from Cape Town on children from 
the original IPT study recently reported additive benefit 
of ART and IPT over 5 years of follow-up. All children on 
placebo were switched to open-label INH and accessed 
ART through the public programme. INH reduced the 
risk of TB by 0.22 (95% CI 0.09 - 0.53) compared with 
placebo. ART alone reduced TB risk by 0.32 (95% CI 
0.07 - 1.55). INH plus ART reduced the risk of TB by 0.11 
(95% CI 0.04 - 0.32). Restricting the analysis to children 
receiving ART revealed a TB risk reduction of 0.23 (95% 
CI 0.05 - 1.00) when comparing INH with no INH.12 This 
study suggests that IPT and ART have additive benefit 
in HIV-infected children.
1. WHO RECOMMENDATIONS
The WHO has recently published guidance on IPT for 
both children and adults, mainly based on adult data.13 
The recommendations for children are as follows:
1.1  Children living with HIV who do not have poor weight 
gain, fever or current cough are unlikely to have 
active TB. 
     Strong recommendation, low quality of evidence
1.2  Children living with HIV and any one of the following 
symptoms – poor weight gain, fever, current cough 
or contact history with a TB case – may have TB and 
should be evaluated for TB and other conditions. 
Once TB is excluded, offer IPT regardless of age.
      Strong recommendation, low quality of evidence
       Comment: All suspected cases MUST be referred 
for exclusion of TB according to local guidelines. 
The timing of this screening is important to avoid 
excessive referrals. A review after 2 weeks may be 
useful before referral. In the complete absence of 
symptoms, no additional work-up is required. 
1.3  Children living with HIV and >12 months of age and 
who are unlikely to have active TB on symptom-
based screening, and have no contact with a TB 
case, should receive 6 months of IPT (10 mg/kg/d) as 
part of a comprehensive package of HIV prevention 
and care services.
      Strong recommendation, moderate quality of 
evidence
      Comment: The implication is that all HIV-infected 
children should receive IPT once active TB has been 
excluded, regardless of their underlying condition. 
This recommendation brings IPT guidelines for 
children in line with those for adults. However, in 
adults, while a duration of 6 months is regarded as 
the minimum period, there is support for 36 months 
or longer. In children, the duration was limited to 6 
months, pending longer-term safety data. The risk 
for TB disease may not be at the time of giving IPT. 
Screening for TB must therefore take place at each 
clinic visit. 
1.4  In children <12 months of age living with HIV, only 
those children in contact with a TB case and in whom 
active TB is excluded should receive 6 months of 
IPT.
      Strong recommendation, low quality of evidence 
      Comment: The contradiction here is that children at 
greatest risk (HIV-infected infants) are not offered the 
same access to IPT as older children. HIV-infected 
infants have a 20 times higher incidence of TB than 
HIV-uninfected infants in a setting of expanding but 
inadequate early identification and access to ART.14 
1.5  All children living with HIV who have successfully 
completed treatment for TB disease should receive 
INH for an additional 6 months.15
      Conditional recommendation, low quality of 
evidence
2. THE IPT WORKING GROUP
The place of IPT for HIV-infected children in Southern 
Africa was debated at a small meeting held in Cape Town 
on 14 October 2010, sponsored by the HIV Clinicians 
Society of South Africa. Paediatricians from South Africa 
and Botswana and adult infectious diseases specialists 
with expertise in IPT attended. (During a review process, 
additional colleagues with expertise in childhood HIV 
and TB gave invaluable input.) The consensus was that 
IPT should be supported. There is a need to define the 
extent to which it should be included. There is a role for 
operational research on IPT. Integration of maternal and 
child health with TB and HIV programmes to accompany 
IPT (Infection control and Intensified case finding) is a 
key component for elimination of TB in children. 
The following should be addressed:
2.1  Who takes responsibility for delivery of IPT?
2.2  How will it be monitored? Key indicators include: 
	 n    uptake
	 n    adherence
	 n    development of TB in children on or not on IPT.
3. RECOMMENDATIONS OF THE IPT  
WORKING GROUP
At each health care visit, every HIV-infected child must 
be reviewed for possible TB exposure and/or active 
disease and managed appropriately. 
Always check the following:
	 n    contact with a TB source case
	 n    failure to thrive (monitor Road to Health Card 
(RTHC))
	 n    present cough (non-remitting cough of ≥2 weeks’ 
duration is suggestive of TB).
4. POST-EXPOSURE IPT
IPT should be provided after EACH documented TB 
exposure, unless the child is CURRENTLY receiving 
INH or TB treatment (Fig. 1).
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4.1  First exclude active TB (see below).
4.2  Give IPT to all HIV-infected children and all children 
less than 5 years of age, regardless of HIV status, 
after exposure to a source case of TB.
4.3  Give INH for 6 months (see dosing below).
Before giving post-exposure IPT, first make sure that 
the child does not have active TB.
n    Completely asymptomatic children (no current cough, 
no failure to thrive, no signs of extrathoracic TB, 
active and playful) require no further investigation 
prior to IPT initiation. (All children receiving IPT 
and/or TB treatment should be followed up clinically 
while on therapy to evaluate for new symptoms or 
signs of disease.)
n    Any symptomatic child should be carefully assessed 
(always plot weight and assess RTHC for failure to 
thrive). In the absence of a convincing clinical picture 
of TB or lethargy, and without easy access to chest 
radiography, first treat the most likely alternative 
diagnosis and re-assess the child after 2 weeks.
n    Persistently symptomatic children must be assessed 
with at least a chest radiograph (antero-posterior 
or postero-anterior AND lateral). Respiratory 
specimens (gastric aspirates and/or induced sputa) 
for M. tuberculosis culture must be collected in 
all children with signs suggestive of TB on chest 
radiograph (prior to initiation of TB treatment).
NOTE: Evaluate for TB using the best resources 
available.
5. PRIMARY (PRE-EXPOSURE) IPT
Primary (pre-exposure) IPT should be given for 6 months 
(Fig. 2). 
5.1  Give under the following circumstances:
n    Active TB excluded (as for post-exposure IPT).
n    Infant/child diagnosed with HIV or ART initiated after 
3 months of age (or poor TB exposure screening 
expected).
5.2.  Do NOT give if ALL of the following criteria are 
fulfilled: 
n    The mother is identified as HIV infected in antenatal 
clinic and screened for TB.
n    No active TB is identified in close contact of the child 
such as member of the household/plot or a regular 
visitor.
n    Infants are initiated on ART under both of the following 
circumstances:
      n    ART initiated within the 1st 3 months of life when 
asymptomatic
      n    active TB excluded.
n    The infant is enrolled in the ART programme and seen 
at least every month for first 3 months and thereafter at 
least every 3 months (with screening for TB exposure 
or signs/symptoms of TB at each visit).
6. CATCH-UP PHASE FOR CHILDREN ALREADY  
ON ART FOR >6 MONTHS
At the time of implementation of the IPT guidelines (June 
2011), there will be 50 000 children on ART. Data support 
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Fig. 1. Management of an HIV-infected child with documented TB exposure or suspected to have TB disease.
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IPT in children.12 For children already well established 
on highly active antiretroviral therapy (HAART) (i.e. >3 
months) and without active TB, there are two options:
6.1  IPT may be given for 6 months. (Apply guidelines 
for new contact with potential source case.) This is 
likely to be most beneficial for those who are TST 
positive (note: in the absence of ART, an induration 
≥5 mm denotes a positive TST (Mantoux)).
6.2  Defer IPT and continue monitoring for new TB 
exposure and signs/symptoms of TB. 
7. DOSAGE
7.1 INH 10 - 15 mg/kg/d.
7.2 Also give vitamin B6 25 mg/d.
8. ADDITIONAL POINTS
8.1  In the absence of obvious TB disease, initiation of 
HAART takes precedence over IPT.
8.2  IPT must NOT complicate the HAART programme.
8.3  ANY child assessed for TB after contact with a TB 
source case must be screened for HIV.
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Fig. 2. Considerations for primary (pre-exposure) IPT.
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Resources for drug-resistant TB: references 16 and 17.
DOSAGE RECOMMENDATIONS FOR IPT (PRIMARY AND POST-EXPOSURE)
